Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3dJSmYd
via IFTTT